Atlas Trials

Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

Clinical trial NCT02740920 · TERMINATED

Trial details

NCT number
NCT02740920
Sponsor
Canadian Cancer Trials Group
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Melanoma
Start date
2017-01-10
Primary completion
2019-03-22
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.